Company Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases.
Its drug candidate, ALG‑055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.
The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG‑097558, a small molecule ritonavir‑free pan‑coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus.
The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven.
Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Oct 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 82 |
| CEO | Lawrence Blatt |
Contact Details
Address: One Corporate Drive, 2nd Floor South San Francisco, California 94080 United States | |
| Phone | 800 466 6059 |
| Website | aligos.com |
Stock Details
| Ticker Symbol | ALGS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001799448 |
| CUSIP Number | 01626L105 |
| ISIN Number | US01626L2043 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lawrence M. Blatt MBA, Ph.D. | Chief Executive Officer, President and Chairman of the Board |
| Dr. Julian A. Symons DPHIL | Executive Vice President and Chief Scientific Officer |
| Nikhil Aneja | Principal Accounting Officer |
| Laura Kavanaugh | Vice President and Head of Legal |
| Kristina Engeseth M.B.A. | Senior Vice President and Head of People and Culture |
| Dr. Sushmita M. Chanda DABT, Ph.D. | Executive Vice President and Chief Development Officer |
| Dr. David B. Smith Ph.D. | Executive Vice President and Head of Chemical Operations |
| Dr. Tse-I Lin Ph.D. | Senior Vice President of Early Compound Development and Belgian Site Head |
| Dr. Kieron Wesson Ph.D. | Vice President and Head of Chemistry Manufacturing Controls |
| Dr. Ramon Polo M.B.A., Ph.D., Pharm.D. | Senior Vice President and Head of Global Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 21, 2026 | 8-K | Current Report |
| Apr 14, 2026 | 8-K | Current Report |
| Mar 5, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 5, 2026 | 10-K | Annual Report |
| Mar 5, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 11, 2026 | SCHEDULE 13G/A | Filing |
| Feb 4, 2026 | 8-K | Current Report |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 6, 2025 | 10-Q | Quarterly Report |